logo-loader

Rakuten Medical receives conditional early approval system review in Japan for head and neck cancer treatment

Published: 14:17 01 Jul 2020 EDT

Rakuten Medical, Inc VP of Global Regulatory Peggy Berry tells Proactive the California-based biotechnology group has received conditional early approval designation for its lead cancer drug from the Japanese Ministry of Health, Labor, and Welfare (MHLW).

Berry says the privately-held group's lead drug ASP-1929, which aims to treat head and neck cancer, is a win for patients.

Coniagas Battery Metals secures new key ground with focus on...

Coniagas Battery Metals (TSX-V:COS) CEO Frank Basa joined Steve Darling from Proactive to announce the company's strategic acquisition of key ground near SOQUEM’s Cardinal Property, located 80 km southeast of Chibougamau, Quebec. This acquisition underscores Coniagas’ commitment to capitalizing...

55 minutes ago